NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Kestra Medical Technologies KMTS

Kestra Medical Technologies listed on Nasdaq on 6 Mar 2025 and is not in the S&P 500. It is worth $1.6 billion. Its board has 8 directors, 6 of them independent. 3 other officers are on file. At 30 Jun 2026, Bain Capital Investors was its largest institutional holder, with 43.1% of the company.

CEO
Brian Daniel Webster
Chair
Jeffrey Lawrence Schwartz
Listed
6 Mar 2025 on Nasdaq
Headquarters
Kirkland, WA
Market cap
$1.6B
19 Nov 2026 close
Revenue
$95M
Fiscal year 2026
Price to sales
16.7
Market cap over revenue

Financials

Financial history

Twelve months to 31 Jul 2026, from Kestra Medical Technologies' quarterly filings.

Quarters since Jul 2024

Revenue
$107M
Up 61% on the year before
Net income
$-150M
-140.4% of revenue
Free cash flow
$-123M
Operating cash flow less capital spending
P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Jul 2024 to Jul 2026

$0$10M$20M$30M$40M202420252026$31M

Kestra Medical Technologies' market cap since March 2025

Marked weeks are changes in the share count, such as a merger, not market moves.

Weekly, up to 13 Nov 2026

Apr 2025JulOctJan 2026AprJulOct$1.7B

Board and leadership

Board and officers

Board from the proxy filed 28 Jul 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (8)
Jeffrey Lawrence SchwartzChairIndependent · since 2023 · Compensation, Nominating and Corporate Governance (chair)Partner and Chief Operating Officer for Global Private Equity, Bain Capital Private Equity, LPChair2023YesCompensation, Nominating and Corporate Governance (chair)47
Brian Daniel WebsterPresident and Chief Executive OfficerNot independent · since 2021President and Chief Executive Officer2021No62
Raymond W. CohenDirectorIndependent · since 2025 · Audit, Compensation (chair)Operating Partner, Star51 Capital and Venture Partner, Andera Partners and Sherpa Capital PartnersOther boards: RxSightDirector2025YesAudit, Compensation (chair)67
Conor HanleyDirectorIndependent · since 2025 · AuditChief Executive Officer, Foundry Innovation & Research 1, Ltd. (FIRE1)Director2025YesAudit57
Elizabeth KwoDirectorIndependent · since 2025 · Nominating and Corporate GovernancePresident, Vanna Health, Inc.Other boards: Walmart de México y CentroaméricaDirector2025YesNominating and Corporate Governance45
Mary Kay LadoneDirectorIndependent · since 2025 · Audit (chair), Nominating and Corporate GovernanceDirectorOther boards: Novanta, Bioventus and InogenDirector2025YesAudit (chair), Nominating and Corporate Governance60
Kevin C. ReillyDirectorIndependent · since 2025 · CompensationManaging Director, Head of Medtech, Ally Bridge GroupDirector2025YesCompensation35
Traci S. UmbergerGeneral Counsel and Chief Adminstrative OfficerNot independent · since 2021General Counsel and Chief Adminstrative Officer2021No63
Officers (3)
Vaseem MahboobChief Financial OfficerLast filed 11 Aug 2026Chief Financial Officer
Alfred J. Ford Jr.Chief Commercial OfficerLast filed 6 Aug 2026Chief Commercial Officer
Timothy P. MoranChief Business OfficerLast filed 3 Aug 2026Chief Business Officer

Owners and trading

Largest institutional holders

Each fund group's share of Kestra Medical Technologies. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 69.7% of Kestra Medical Technologies.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $16.0 million of stock in 44 sales and bought $199,800 in 1 purchase in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
18 Nov 2026SaleBrian Daniel WebsterPresident and Chief Executive OfficerPresident and Chief Executive OfficerSale15,000$427K
3 Nov 2026SaleTimothy P. MoranChief Business OfficerChief Business OfficerSale3,192$94K
29 Oct 2026SaleVaseem MahboobChief Financial OfficerChief Financial OfficerSale4,788$147K
28 Oct 2026SaleVaseem MahboobChief Financial OfficerChief Financial OfficerSale39,903$1.2M
27 Oct 2026SaleVaseem MahboobChief Financial OfficerChief Financial OfficerSale34,809$1.0M
27 Oct 2026SaleTraci S. UmbergerGeneral Counsel and Chief Adminstrative OfficerGeneral Counsel and Chief Adminstrative OfficerSale30,000$901K
21 Oct 2026SaleTraci S. UmbergerGeneral Counsel and Chief Adminstrative OfficerGeneral Counsel and Chief Adminstrative OfficerSale100,000$2.7M
20 Oct 2026SaleBrian Daniel WebsterPresident and Chief Executive OfficerPresident and Chief Executive OfficerSale15,000$443K
30 Sep 2026SaleRaymond W. CohenDirectorDirectorSale3,330$98K
21 Sep 2026SaleElizabeth KwoDirectorDirectorSale4,010$97K

Showing 10 of 45 trades

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

0 departures and 1 appointment of directors and officers and 5 large insider sales in the last two years.

Left the company or board 0Appointed 1WARN layoff notices 0Large insider sales 5Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Kestra Medical Technologies' insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.